Integrative transcriptome analysis identifies genes and pathways associated with enzalutamide resistance of prostate cancer

References

• Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–2917.
   PubMed Web of Science ®Google Scholar
• Bluemn EG, Nelson PS. The androgen/androgen receptor axis in prostate cancer. Curr Opin Oncol. 2012;24:251–257.
   PubMed Web of Science ®Google Scholar
• Shtivelman E, Beer TM, Evans CP. Molecular pathways and targets in prostate cancer. Oncotarget. 2014;5:7217–7259.
   PubMed Web of Science ®Google Scholar
• Ross RW, Xie W, Regan MM, et al. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer. 2008;112:1247–1253.
   PubMed Web of Science ®Google Scholar
• Klotz L, Toren P. Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care? Curr Oncol. 2012;19:S13–S21.
   PubMed Web of Science ®Google Scholar
• Harris WP, Mostaghel EA, Nelson PS, et al. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009;6:76–85.
   PubMedGoogle Scholar
• Suzman DL, Antonarakis ES. Castration-resistant prostate cancer: latest evidence and therapeutic implications. Ther Adv Med Oncol. 2014;6:167–179.
   PubMed Web of Science ®Google Scholar
• Chandrasekar T, Yang JC, Gao AC, et al. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Trans Androl Urol. 2015;4:365–380.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Petrylak DP, Madan RA, et al. Progress in the treatment of advanced prostate cancer. American Society of Clinical Oncology Educational Book American Society of Clinical Oncology Meeting; 2014 Jun 3; Chicago, IL. p. 117–131.
   PubMedGoogle Scholar
• Rodriguez-Vida A, Galazi M, Rudman S, et al. Enzalutamide for the treatment of metastatic castration-resistant prostate cancer. Drug Design Dev Ther. 2015;9:3325–3339.
   PubMed Web of Science ®Google Scholar
• Kregel S, Chen JL, Tom W, et al. Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer. Oncotarget. 2016;7:26259–26274.
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–1197.
   PubMed Web of Science ®Google Scholar
• Beer TM, Tombal B. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:1755–1756.
   PubMed Web of Science ®Google Scholar
• Simon R. Analysis of DNA microarray expression data. Best Pract Res Clin Haematol. 2009;22:271–282.
   PubMed Web of Science ®Google Scholar
• Costouros NG, Libutti SK. Microarray technology and gene expression analysis for the study of angiogenesis. Exp Opin Biol Ther. 2002;2:545–556.
   PubMed Web of Science ®Google Scholar
• Simon R. Microarray-based expression profiling and informatics. Curr Opin Biotechnol. 2008;19:26–29.
   PubMed Web of Science ®Google Scholar
• Li X, Thomason PA, Withers DJ, et al. Bio-informatics analysis of a gene co-expression module in adipose tissue containing the diet-responsive gene Nnat. BMC Syst Biol. 2010;4:175.
   PubMed Web of Science ®Google Scholar
• Barfeld SJ, East P, Zuber V, et al. Meta-analysis of prostate cancer gene expression data identifies a novel discriminatory signature enriched for glycosylating enzymes. BMC Med Genomics. 2014;7:513.
   PubMedGoogle Scholar
• Rhodes DR, Barrette TR, Rubin MA, et al. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res. 2002;62:4427–4433.
   PubMed Web of Science ®Google Scholar
• Reimand J, Arak T, Adler P, et al. g:Profiler-a web server for functional interpretation of gene lists (2016 update). Nucleic Acids Res. 2016;44:W83–W89.
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Yu J, Shanker K, et al. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci USA. 2004;101:9309–9314.
   PubMed Web of Science ®Google Scholar
• Wang J, Duncan D, Shi Z, et al. WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013. Nucleic Acids Res. 2013;41:W77–W83.
   PubMed Web of Science ®Google Scholar
• Gene Ontology C, Blake JA, Dolan M, et al. Gene Ontology annotations and resources. Nucleic Acids Res. 2013;41:D530–D535.
   PubMed Web of Science ®Google Scholar
• Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28:27–30.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. Cancer J Clin. 2016;66:7–30.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. Cancer J Clin. 2015;65:5–29.
   PubMed Web of Science ®Google Scholar
• Lee AJ, Endesfelder D, Rowan AJ, et al. Chromosomal instability confers intrinsic multidrug resistance. Cancer Res. 2011;71:1858–1870.
   PubMed Web of Science ®Google Scholar
• Sansregret L, Patterson JO, Dewhurst S, et al. APC/C dysfunction limits excessive cancer chromosomal instability. Cancer Discov. 2017;7:218–233.
   PubMed Web of Science ®Google Scholar
• Gao Y, Cimica V, Reich NC. Suppressor of cytokine signaling 3 inhibits breast tumor kinase activation of STAT3. J Biol Chem. 2012;287:20904–20912.
   PubMed Web of Science ®Google Scholar
• Rossa C Jr, Sommer G, Spolidorio LC, et al. Loss of expression and function of SOCS3 is an early event in HNSCC: altered subcellular localization as a possible mechanism involved in proliferation, migration and invasion. PLoS One. 2012;7:e45197.
   PubMed Web of Science ®Google Scholar
• Handle F, Erb HH, Luef B, et al. SOCS3 modulates the response to enzalutamide and is regulated by androgen receptor signaling and CpG methylation in prostate cancer cells. Mol Cancer Res. 2016;14:574–585.
   PubMed Web of Science ®Google Scholar
• Gurrieri C, Capodieci P, Bernardi R, et al. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst. 2004;96:269–279.
   PubMedGoogle Scholar
• Yang L, Yeh SD, Xie S, et al. Androgen suppresses PML protein expression in prostate cancer CWR22R cells. Biochem Biophys Res Commun. 2004;314:69–75.
   PubMed Web of Science ®Google Scholar